Neimeth PLC

Neimeth PLC, formally known as Neimeth International Pharmaceuticals PLC, is a Nigerian pharmaceutical company headquartered in Lagos. The company was established in 1997 after Pfizer's global repositioning reduced its emphasis on over-the-counter medicines. A management buyout led to the creation of a new Nigerian company that acquired selected trading assets associated with Pfizer International's Nigerian operations. The business was named Neimeth in recognition of a Pfizer executive who had supported the Nigerian operation. The company's origins lie in Pfizer's long presence in Nigeria. Pfizer began operating in the country in 1957, initially importing branded medicines including Terramycin. In 1962, it opened a manufacturing plant in Aba, described in the available reference material as the first pharmaceutical factory in British West Africa. Production at Aba was affected by the Nigerian Civil War, after which Pfizer invested in a new facility at Oregun in Lagos. The Lagos plant broadened the company's manufacturing capabilities, including the production of injectable medicines. During the 1990s, the Nigerian pharmaceutical market changed significantly. Imported generic medicines, particularly products from Asian suppliers, increased competitive pressure on established branded manufacturers. At the same time, consumption of over-the-counter medicines expanded. Pfizer's Nigerian operation consequently shifted some attention away from relationships with hospitals and pharmacists centered on prescription products and toward over-the-counter medicines sold through drug stores and other retail channels. Neimeth inherited this commercial and manufacturing background when it was formed. At its inception, Neimeth manufactured medicines licensed from Pfizer International. Over time, it also developed internal research and product-development capabilities. The available reference material states that by 2009, products generated through the company's in-house research represented approximately 30 percent of revenue, although no financial source or detailed revenue series is provided here. One of the best-known internally developed offerings is Ciklavit, an herbal remedy intended to support management of sickle-cell crises and based on Cajanus cajan. Ciklavit is associated with the company's Neimeth Product Group, a strategic business unit that also markets generic medicines such as Normoretic and Flexodene. The company experienced a difficult period during the middle of the 2010s, including losses and a fire that destroyed an entire stock of raw materials. The available material does not provide enough information to quantify the losses, identify the facility, or establish the fire's precise date. Neimeth remains characterized in the reference material as a Nigerian publicly listed pharmaceutical business with activities spanning manufacturing, proprietary or internally researched products, licensed medicines, and generic offerings. Detailed current information about its website, executive leadership, ownership structure, market capitalization, product-registration portfolio, and international operations is not established by the supplied sources.

Neimeth's history is rooted in Pfizer's Nigerian operations rather than in a completely new pharmaceutical venture. Pfizer entered Nigeria in 1957 by importing branded medicines, including Terramycin. Five years later, it established a factory at Aba. The facility represented an early milestone in Nigerian pharmaceutical manufacturing and is described in the available reference material as the first pharmaceutical factory in British West Africa. The Nigerian Civil War disrupted manufacturing at Aba. In response, Pfizer committed further investment to a replacement or expanded manufacturing base at Oregun in Lagos. The Oregun plant enabled a wider product range, including injectable drugs, and helped establish the industrial and commercial platform from which the later Neimeth business developed. By the 1990s, the operating environment had become more competitive. Imported generic medicines, including products from Asia, competed with locally manufactured and branded medicines. Pfizer's Nigerian business had traditionally relied substantially on relationships with pharmacists and hospitals, especially for prescription products. However, increasing over-the-counter consumption and the growing availability of imported generics encouraged a shift toward non-prescription medicines and distribution through drug stores and other over-the-counter retail outlets. In 1997, Pfizer's global repositioning away from over-the-counter drugs resulted in a management buyout of majority shares in the Nigerian operation. The resulting company was named Neimeth International Pharmaceuticals, with the name honoring a Pfizer executive associated with support for the Nigerian business. Neimeth initially continued to manufacture products licensed from Pfizer International, preserving a connection with the predecessor operation while operating as a separate Nigerian company. The company later expanded its emphasis on internal research and development. The reference material reports that by 2009, products arising from Neimeth's own research accounted for about 30 percent of revenue. The most prominent example identified is Ciklavit, an herbal remedy for sickle-cell crisis management whose active ingredient is Cajanus cajan. Ciklavit was marketed through the Neimeth Product Group, a strategic business unit that also handled generic products including Normoretic and Flexodene. Neimeth encountered financial and operational difficulties during the middle of the 2010s. The company went through a period of losses, and a fire destroyed an entire stock of raw materials at one point. The supplied material does not provide a precise year, financial amount, or detailed account of the incident. Consequently, the event is recorded as an operational setback rather than as a scandal or a quantified financial milestone. The available sources present Neimeth as a publicly listed Nigerian pharmaceutical company with a business spanning medicines inherited from or licensed through the Pfizer relationship, generic products, over-the-counter offerings, and internally researched remedies. They do not establish a complete account of later corporate developments, current management, ownership, geographic expansion, or present product registrations.

• 2009

  Internal research becomes a significant revenue contributor

  [1]Neimeth PLCen.wikipedia.org

  The reference material reports that products from Neimeth's in-house research accounted for approximately 30 percent of revenue.

• 1997

  Neimeth is established

  [1]Neimeth PLCen.wikipedia.org

  A management buyout of majority shares follows Pfizer's global repositioning away from over-the-counter medicines, creating Neimeth International Pharmaceuticals.

• 1962

  Aba pharmaceutical factory opens

  [1]Neimeth PLCen.wikipedia.org

  Pfizer opens a manufacturing plant at Aba, described by the reference as the first pharmaceutical factory in British West Africa.

• 1957

  Pfizer begins operations in Nigeria

  [1]Neimeth PLCen.wikipedia.org

  Pfizer starts operating in Nigeria by importing branded medicines, including Terramycin.

• Manufacturing shifts toward Lagos

  [1]Neimeth PLCen.wikipedia.org

  After the Nigerian Civil War affected production at Aba, Pfizer invests in a new Oregun facility in Lagos, expanding production to include injectable medicines.

• Raw-material inventory is destroyed in a fire

  [1]Neimeth PLCen.wikipedia.org

  During the company's difficult period in the middle of the 2010s, a fire destroyed an entire stock of raw materials. The precise date and financial impact are not specified.

A Nigerian pharmaceutical manufacturer and marketer combining inherited Pfizer-related products with generic medicines and locally developed offerings, including an herbal sickle-cell crisis management product.

• Herbal remedy

  Ciklavit

  Ciklavit is an internally researched herbal product associated with management of sickle-cell crises. The reference material identifies Cajanus cajan as its active ingredient and places the product within Neimeth's Neimeth Product Group. The supplied sources do not establish its complete formulation, regulatory status, launch date, dosage information, or current availability.

• Generic pharmaceutical

  Normoretic

  Normoretic is identified as a generic medicine marketed through the Neimeth Product Group. The available reference does not specify its active ingredients, therapeutic indication, dosage form, launch year, or current distribution footprint, so it is listed here only as a documented Neimeth generic offering.

• Generic pharmaceutical

  Flexodene

  Flexodene is identified in the reference material as another generic offering marketed through Neimeth's Product Group. No reliable product-level details about its ingredients, indication, formulation, launch date, or present status are supplied.

• 1997

  Management buyout creates an independent Nigerian pharmaceutical companyStrategy

  Background

  Pfizer's global repositioning away from over-the-counter medicines created the conditions for a management buyout of majority shares in its Nigerian operation.

  Action taken

  The acquired operation was reorganized as Neimeth International Pharmaceuticals and continued manufacturing some medicines licensed from Pfizer International.

  Aftermath

  The transaction established the corporate identity and operating foundation of Neimeth PLC.

  Source

• Shift toward over-the-counter and retail distributionStrategy

  Background

  Imported generics and rising over-the-counter consumption changed the competitive conditions in Nigeria during the 1990s.

  Action taken

  The predecessor operation increased emphasis on over-the-counter products and sales through drug stores and other non-prescription retail channels.

  Aftermath

  This market orientation formed part of the commercial background inherited by Neimeth after its establishment.

  Source

1. 1Neimeth PLCen.wikipedia.org